It’s time to pull together some notes, ideas, and clinical data on various biomarkers based on data available from clinical studies in oncology R&D and see how much progress we are making.
Are biomarkers a good path to success in cancer research or are they a gloomy red herring to the road less travelled?
Both answers can be equally true, but how do we tell the difference? Are there any clues that we can use ahead of time to avoid later disappointment?
There have been several early studies that we’ve been following lately with readouts available from numerous cancer conferences, both positive and negative.
Can we learn from the failures and successes of the past to better interpret outcomes from future trials?